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Whether mouse models of chronic asthma can be used to investigate the relationship
between airway inflammation/remodeling and airway hyper-responsiveness (AHR) is a
vexed question. It raises issues about the extent to which such models replicate key
features of the human disease. Here, we review some of the characteristic pathological
features of human asthma and their relationship to AHR and examine some limitations
of mouse models that are commonly used to investigate these relationships. We
compare these conventional models with our mouse model of chronic asthma involving
long-term low-level inhalational challenge and review studies of the relationship between
inflammation/remodeling and AHR in this model and its derivatives, including models of
an acute exacerbation of chronic asthma and of the induction phase of childhood asthma.
We conclude that while extrapolating from studies in mouse models to AHR in humans
requires cautious interpretation, such experimental work can provide significant insights
into the pathogenesis of airway responsiveness and its molecular and cellular regulation.
Keywords: airway hyper-responsiveness, airway inflammation, airway remodeling, animal models, asthma
INTRODUCTION
Mouse models can certainly be employed to investigate the rela-
tionship between asthmatic inflammation/airway remodeling and
airway hyper-responsiveness (AHR): they have been and continue
to be used for such research. Whether they should be, i.e., whether
the models are sufficiently similar to the human disease to be suit-
able for the purpose, is a separate question altogether. It raises, in
turn, questions about the extent to which such models replicate
key features of the human disease and about what exactly is being
measured when AHR is assessed in animals. This review focuses
on the first of those considerations: technical issues related to the
measurement of AHR in mouse models and their relevance to
physiological assessment in humans are examined elsewhere in
this issue.
Whether mouse models replicate the features of human
asthma with sufficient fidelity is a critically important question,
which needs to be addressed both by experimentalists and by
journal reviewers. Of course all experimental models have limita-
tions, but if the model being investigated is not appropriate to the
outcomes being assessed, it may be difficult to extrapolate from
the experimental data to the human disease. While this has led
some to suggest that mouse models of asthma have yielded little
that has been able to be translated into improvements in ther-
apy (Persson, 2002; Boyce and Austen, 2005; Wenzel and Holgate,
2006), many of the carefully performed studies in mouse mod-
els have yieldedmuch interesting information about pathogenetic
mechanisms of asthma.
To advance discussion about the relevance of mouse mod-
els, it would be appropriate to briefly review the characteristic
pathological features of human asthma and their relationship to
AHR. Some limitations of commonly used mouse models can
then be examined, and the merits of a potential approach to
overcoming these limitations can be assessed. In drawing com-
parisons, it is worth emphasizing that available mouse models are
largely relevant only to allergic/eosinophilic asthma in humans.
The overwhelming majority of children with asthma have evi-
dence of allergy/atopy, but asthma of adult onset is frequently
non-eosinophilic (Kumar and Jeffery, 2012). The pathological
features described below relate to human allergic asthma.
AIRWAY INFLAMMATION IN ASTHMA
Airway inflammation is a characteristic feature of human asthma.
The pathological changes are in general restricted to the conduct-
ing airways, mostly involving major bronchi, but also smaller air-
ways in severe disease (James, 2009). Alveolar inflammation has
been described in some settings (Kraft et al., 1996; De Magalhaes
Simoes et al., 2005), but it should be emphasized that asthma is
not primarily a condition involving the lung parenchyma.
Even in the earliest stages of mild clinical asthma, there is
accumulation of chronic inflammatory cells in the mucosa of the
larger conducting airways (Holgate et al., 1992; Laitinen et al.,
1993). These include increased numbers of lymphocytes, plasma
cells, mast cells, and macrophages. As has long been empha-
sized, in allergic asthma the majority of lymphocytes within the
airway wall are CD4+ cells which exhibit a T helper type 2
(Th2) profile of cytokine secretion, characterized by production
of interleukin (IL)-4, IL-5, and IL-13 (Hamid et al., 1991; Yung
et al., 1995). Lymphocytes and mast cells are also prominent
deeper in the airway wall, including in the smooth muscle layer
(Brightling et al., 2002; Begueret et al., 2007). Superimposed upon
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this background is an acute inflammatory component, which
is typically associated with recruitment of eosinophils into the
mucosa (Bradley et al., 1991; Shaver et al., 1997) and in par-
ticular into the epithelial layer (Figure 1). Indeed, intraepithelial
eosinophils are considered to be a distinctive feature of asthmatic
inflammation (Bousquet et al., 1990), whereas recruitment of
neutrophils into the airways is uncommon in mild to moderate
asthma.
In patients with asthma, there has long been controversy about
whether airway inflammation correlates with AHR (Sont et al.,
1996; Crimi et al., 1998). This may in part be a consequence
of the use of different stimuli to assess airway responses. AHR
to indirect stimuli, such as distilled water, hypertonic saline, or
mannitol, seems to correlate more closely with airway inflamma-
tion than does the response to bronchoconstrictor agents (Chetta
et al., 1996; Joos et al., 2003).
INVESTIGATING THE RELATIONSHIP BETWEEN
INFLAMMATION AND AHR IN MOUSE MODELS
Most mouse models of asthma involve short-term challenge of
sensitized mice with antigen delivered either by inhalational expo-
sure that is uncontrolled (i.e., with no attempt made to limit the
mass concentration of aerosol to which the animals are exposed
and no monitoring of the concentration of aerosol in the breath-
ing zone of the animals) or intratracheally. These models are
experimentally convenient, but given the nature of the anti-
genic challenge, they are primarily models of severe acute allergic
inflammation. Thus they are very useful for investigating the basis
of allergic inflammation, including the role of CD4+ Th2 cells,
as well as the various cellular and molecular pathways involved
in regulating their activity. However, there are important differ-
ences in the pattern of airway inflammation compared to human
asthmatics. Notably, inflammation is by no means limited to the
conducting airways, but is usually associated with accumulation
FIGURE 1 | Bronchus from an asthmatic patient, demonstrating
numerous eosinophils, both within the airway epithelium and in the
underlying lamina propria. Note the marked goblet cell change in the
epithelium and the prominent zone of subepithelial fibrosis. Hematoxylin
and eosin.
of large numbers of perivascular inflammatory cells, as well as
with marked edema around blood vessels (Figure 2). The severity
and extent of peribronchiolar inflammation are variable. There is
also a relative over-representation of eosinophils, which comprise
40–80% of the cells in the bronchoalveolar lavage fluid (BALF)
of these mice, in contrast to the 1–5% eosinophils in BALF from
human asthmatics.
Importantly, chronic inflammation of the airway wall is con-
spicuously absent in these models, which means that they cannot
be used for investigation of the relationship between chronic air-
way inflammation and AHR. Thus their relevance is likely to be
limited to AHR in severe asthma or exacerbations of asthma,
subject of course to the problems associated with the lack of com-
parability of techniques used to assess AHR in mice as compared
to humans. There are also questions about the relative contri-
bution of changes in large vs. small airways to the AHR that is
able to be demonstrated. Ex vivo studies in these mouse mod-
els have provided evidence of altered contractility of bronchial
smooth muscle in response to allergen or a non-specific bron-
choconstrictor agent (Chiba et al., 2005; Chew et al., 2008)
and a component of AHR, measured using the most appro-
priate available techniques, undoubtedly does originate from
the conducting airways. However, it has been suggested that in
short-term models, AHR may at least in part be explained on
the basis of thickening of the airway mucosa and an increased
propensity of small airways to close, without any increase in
the degree of airway smooth muscle shortening (Wagers et al.,
2004; Lundblad et al., 2007). Notwithstanding this caveat, air-
way closure in response to a bronchoconstrictor challenge is
also a contributory mechanism of AHR in human asthmatics
(Berend et al., 2008).
It is also important to realize that the information which
may be gained from the use of mouse models to investigate
FIGURE 2 | Lung tissue demonstrating the inflammatory response in a
conventional mouse model of allergic airway inflammation. Following
short-term, uncontrolled inhalational challenge of a sensitized animal with
aerosolized ovalbumin, there is marked perivascular inflammation (below,
right) and edema (right) but relatively limited peribronchiolar inflammation.
Hematoxylin and eosin.
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development of AHR is influenced by key experimental vari-
ables such as the time point of examination after allergen
challenge. For example, we have shown that prolonged AHR
(i.e., altered responsiveness detectable at 1 week after allergen
challenge, demonstrable as primarily originating from the con-
ducting airways) may largely be driven by an interaction between
interferon-γ and pulmonary macrophages rather than involving
eosinophilic inflammation (Yang et al., 2010).
AIRWAYWALL REMODELING IN ASTHMA
Pathological remodeling in asthma refers to structural changes
in the airway wall. Early on, even in mild or moderate asthma,
there is prominent thickening of a fibrillary layer subjacent to the
epithelium, which is highly characteristic of the disease (Jeffery,
2001). This is primarily associated with deposition of type III and
type V collagens, together with other matrix proteins including
laminins (Altraja et al., 1996), tenascin (Laitinen et al., 1997),
periostin (Takayama et al., 2006), and a variety of proteoglycans.
It is variously referred to as subepithelial fibrosis or thickening of
the reticular basement membrane (RBM) and is associated with
evidence of Th2-driven allergic inflammation (Woodruff et al.,
2009) and the presence of increased numbers of subepithelial
myofibroblasts (Brewster et al., 1990). At least in large airways,
RBM thickness correlates well with overall thickening of airway
wall, so that assessment of the thickness of the subepithelial layer
in bronchial biopsies may be a useful indicator of airway remod-
eling (James et al., 2002). However, its relevance to functional
changes in asthma is unclear, and recent investigations suggest
that subepithelial thickening may be a consequence of bron-
choconstriction rather than a contributor to airflow obstruction
(Grainge et al., 2011).
Perhaps the most important feature of asthmatic airway
remodeling is thickening of the airway smooth muscle layer
(James and Carroll, 2000; James et al., 2012). This includes hyper-
trophy and hyperplasia of the muscle cells, as well as altered
deposition of extracellular matrix (Woodruff et al., 2004; Begueret
et al., 2007; Pini et al., 2007; Hassan et al., 2010). Increased
smooth muscle mass is highly likely to contribute to AHR because
thickening of the airway wall may decrease the degree of airway
smooth muscle shortening required to occlude the lumen (James
et al., 1989; James andWenzel, 2007).
Airway mucosal vascularity, especially increased density of
newly formed small vessels, is also a feature of remodeling in mild
to moderate asthma (Li and Wilson, 1997; Salvato, 2001; Feltis
et al., 2006). These vessels may have increased permeability and
thus contribute to airway wall edema leading to airflow obstruc-
tion (Khor et al., 2009), although the relevance of this to AHR is
unknown.
Another characteristic feature of remodeling in human asth-
matics is an increase in the number of mucin-secreting goblet
cells in the surface epithelium, due to both hyperplasia and meta-
plasia (the latter representing altered differentiation and seen
mostly in small airways; Ordonez et al., 2001). Again, the rela-
tionship between these changes and AHR in patients has not
been defined, further emphasizing that the relationship between
airway remodeling and AHR in asthmatics remains poorly
understood.
INVESTIGATING THE RELATIONSHIP BETWEEN
REMODELING AND AHR IN MOUSE MODELS
As noted above, most commonly used mouse models involve
short-term challenge of sensitized animals with large amounts
of antigen, triggering severe acute allergic inflammation.
Unsurprisingly, such models replicate few features of airway
remodeling, although mucous cell change is a very rapidly
developing response (Ohkawara et al., 1997) and some stud-
ies have yielded interesting information about its potential role
in AHR (Nakanishi et al., 2001; Long et al., 2006). In the past
dozen years, a number of investigators have sought to develop
better animal models based on extending the period of anti-
genic challenge to 4–8 weeks (Braun et al., 1999; Hogaboam et al.,
2000; Tanaka et al., 2001; Henderson et al., 2002; Jain et al.,
2002; Leigh et al., 2002; Kenyon et al., 2003; Johnson et al., 2004;
Pitchford et al., 2004; Yang et al., 2004; McMillan et al., 2005;
Wegmann et al., 2005; Locke et al., 2007; Shinagawa et al., 2007).
Many of these do exhibit various features of airway wall remodel-
ing: most reports describe marked goblet cell change and several
also demonstrate evidence of increased airway smooth muscle. A
single study reported increased airway vascularity in such a model
(Su et al., 2008).
However, almost all of these chronic challengemodels still have
shortcomings. Notably, because of the unregulated exposure to
high mass concentrations of inhaled antigen, repeated challenge
is frequently associated with severe pulmonary inflammation,
sometimes with formation of multinucleated giant cells and even
granulomas (Mathew et al., 2001). This response appears to
be somewhat variable and possibly dependent on the strain of
mice used, because several reports suggest that there may instead
be progressive downregulation of airway inflammation and Th2
responses (Irifune et al., 1998; Yiamouyiannis et al., 1999; Sakai
et al., 2001; Leigh et al., 2002; Pitchford et al., 2004). Furthermore,
the marked peribronchiolar accumulation of collagen that is
observed in such models is quite distinct from the limited zone
of subepithelial thickening in conducting airways that is charac-
teristic of human asthma. This peribronchiolar scarring, which
often extends further including around blood vessels, is not
synonymous with subepithelial fibrosis, despite the widespread
misuse of the term by investigators, and should instead be
described as airway wall fibrosis. Although small airway remod-
eling has been demonstrated in severe asthmatics (Dolhnikoff
et al., 2009), airway fibrosis is not a characteristic lesion of human
asthma. Clearly, it would be unwise to draw conclusions about
the relationship between airway remodeling and AHR in such
a setting.
A MORE REALISTIC MOUSE MODEL OF MILD
CHRONIC ASTHMA
We have described a mouse model of chronic asthma that
involves long-term challenge of sensitized mice with carefully
controlled low mass concentrations of aerosolized ovalbumin
(approximately 3mg/m3 which is some 100–1000 times lower
than used in conventional models; Temelkovski et al., 1998).
This exhibits changes of chronic asthma that closely resemble the
human disease, both in terms of pattern and spatial distribution
of cellular responses. Airway disease is established by 4 weeks
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of inhalational challenge (30min/day, 3 days/week) with lesions
including eosinophil recruitment into the epithelial layer of the
conducting airways, chronic inflammation in the airway wall with
accumulation of T-lymphocytes and plasma cells, and changes
of remodeling such as sub-epithelial fibrosis, epithelial hypertro-
phy, and goblet cell metaplasia. Importantly, there is minimal
parenchymal inflammation, i.e., no perivascular or peribronchio-
lar inflammation in the lungs (Temelkovski et al., 1998). In terms
of pathogenesis, in this model there is clearly a role for both
Th2 and Th1 cytokines, as demonstrated in studies using gene-
targeted animals and neutralizing antibodies (Kumar et al., 2002,
2004a,c). This model has, therefore, been widely acknowledged
to represent a significant improvement in terms of the fidelity
with which it reproduces features of human asthma (Shore, 2003;
Fulkerson et al., 2005; Nials and Uddin, 2008).
Can this model be used to investigate the pathogenesis of AHR
and, in particular, its relationship to airway remodeling? Our
studies suggest that, at the very least, the cytokine mechanisms
involved in development of AHR following low-level chronic
challenge may be different to those demonstrated in short-term
models assessed at early time points after challenge, because there
appears to be less dependency on Th2 responses and a significant
role for interferon-γ (Kumar et al., 2004c). Moreover, although
the presence of airway remodeling is often correlated with evi-
dence of AHR, we have clearly demonstrated that these may be
dissociated (Foster et al., 2000). We would not suggest that this
model provides definitive answers, as we have previously identi-
fied some important limitations. Unlike chronic exposure models
in which antigenic challenge is uncontrolled, we find no evi-
dence of significant hypertrophy or hyperplasia of airway smooth
muscle (Kumar et al., 2004b), which limits comparability to the
human disease. In addition, as in other models in mice, there is
no evidence of accumulation of mast cells in the airways (Kumar
et al., 2000) so the potential contribution of these cells cannot be
properly assessed.
MODELING OTHER ASPECTS OF ASTHMA
Using our chronic challenge model as a substrate, we have also
established a model of an allergen-induced acute exacerbation
of chronic asthma, in which following low-level challenge for
4 weeks, animals were exposed for a 30-min period to a sin-
gle challenge with 30mg/m3 of aerosolized antigen (i.e., 10-fold
higher than usual). This moderate-level challenge is associated
with more marked airway inflammation, which extends fur-
ther distally than in the chronic challenge model (Siegle et al.,
2006). Compared to short-term uncontrolled challenge models,
however, the inflammatory response is relatively mild and the
numbers of eosinophils, lymphocytes and neutrophils in BALF
aremodest. Table 1 compares some key features of the human dis-
ease with short-term, high-level challenge models and the models
that we have developed.
Does our model permit investigation of the pathogenesis of
AHR in patients with an acute exacerbation of chronic asthma?
Quite possibly, because these animals demonstrate a pattern of
AHR distinct from that seen in the chronic challenge model, pre-
sumably reflecting the distal airway involvement (Siegle et al.,
2006). Development of AHR appears not to be dependent on
eosinophil recruitment and is relatively resistant to treatment
with glucocorticosteroids (Ito et al., 2008).
More recently, we have extended the approach of using con-
trolled inhalational challenge to studies seeking to model the
induction phase of asthma in childhood, with sensitization early
in life via the respiratory tract. Because inhalational sensitiza-
tion/challenge with an innocuous protein antigen such as oval-
bumin does not elicit an allergic immunological response and
indeed may lead to tolerance (Gerhold et al., 2003; Wang and
McCusker, 2006), early life airway epithelial injury by envi-
ronmental factors, which promotes sensitization, appears to be
essential for the development of features of asthma. We have
demonstrated a crucial interaction between neonatal respira-
tory viral infection and respiratory sensitization/challenge in the
pathogenesis of an asthmatic phenotype (Siegle et al., 2010) and
have subsequently also investigated the role of early life exposure
to environmental particulates in progression to an asthmatic pat-
tern of inflammation (Herbert et al., submitted for publication).
These studies have highlighted the likely importance of persistent
epithelial injury in the development of AHR in such models.
THE BOTTOM LINE
A reasonable answer to the question “Can mouse models be
used to investigate the relationship between airway inflam-
mation/remodeling and AHR?” is: up to a point, but it is
important to recognize the associated problems and limitations.
Both researchers and referees need to be alert to such issues.
Table 1 | Comparison of human asthma and various mouse models.
Chronic human Mouse model of Short-term Human acute Mouse model of
asthma chronic asthma∗ mouse models exacerbation acute exacerbation∗
Eosinophils in BALF + ± + + ++ ++ +
Lymphocytes in BALF + + + ++ ++
Neutrophils in BALF − − ++ ++ ++
Chronic inflammation in tissue + + − + +
Airway wall remodeling + + − + +
Distal airway inflammation − − + + + + +
AHR originating from distal airways − − ++ + +
∗These columns refer to the models that we have developed, as described in the text.
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As an example, smooth muscle changes that appear to be impor-
tant in the development of AHR in human asthmatics are not
reproduced at all well in mouse models except when associated
with numerous confounding lesions, which are often ignored.
Similarly, the literature contains many reports of studies in which
severe peribronchiolar fibrosis is used as an index of remodeling
and is then correlated with effects on AHR, yet such fibrosis is not
a feature of the airways in patients with asthma. A lack of appre-
ciation of the pathological changes in human asthma can lead to
the use of suboptimal animal models and avoidable weaknesses in
experimental design.
Given the complexity of asthma, however, it will always be the
case that no single animal model—in mice or any other species—
will be a perfect system for studies of the pathogenesis of AHR
or any other aspect of the human disease. For experimentalists
to be able to design/select mouse models that are appropriate for
the investigation of the question of interest, this complexity needs
to be unraveled. Experimental work focusing on Th2-mediated
responses was driven by the recognition that this was a key feature
of inflammation in the airways of human asthmatics. However,
current approaches to stratifying inflammatory phenotypes of
asthma in patients (e.g., based on examination of induced spu-
tum) cannot readily be translated to mouse models. In turn,
this means that translation of experimental findings back to the
appropriate subset of patients is difficult. Phenotyping of asthma
based on pathological changes at the cellular and molecular level,
rather than on clinical manifestations and assessment of pul-
monary function, is likely to facilitate the design of better studies
using appropriate mouse models that shed light on pathogen-
esis, which in turn can lead to the development of worthwhile
therapeutic interventions.
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